1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,050 | 1,084 | 21:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Nanoform senkt Cashburn im dritten Quartal, Aktie gibt dennoch nach | 12 | Investing.com Deutsch | ||
| NANOFORM FINLAND Aktie jetzt für 0€ handeln | |||||
| 12.11. | Nanoform Finland Oyj Q3 Sales Decline | 2 | RTTNews | ||
| 12.11. | Nanoform Finland Oyj: Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set | 1.390 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | November 12, 2025 at 08:10:00 EET
Our product kernels see good momentum. Nanoenzalutamide progresses with the fed arm of the pivotal human study. Licensing and... ► Artikel lesen | |
| 11.11. | Nanoform Finland Oyj: Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License | 373 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | November 11, 2025 at 08:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that... ► Artikel lesen | |
| 27.10. | Nanoform Finland Oyj: Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma | 586 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 27, 2025 at 09:10:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced a partnership... ► Artikel lesen | |
| 14.10. | Nanoform Finland Oyj: Nanoform Outlicenses Nanoencorafenib And Signs Development And Commercialisation Agreement With A.forall And IMGA | 646 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 14, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| 30.09. | Nanoform Finland Oyj: Nanoform Expands Commercial Presence In Asia With A&ls Pharma In South Korea | 616 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | September 30, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced it has entered... ► Artikel lesen | |
| 21.08. | Nanoform Finland Oyj: Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results | 1.500 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | August 21, 2025 at 08:10:00 EEST
First preliminary pivotal study results supportive for project Nanoenzalutamide to continue to progress towards the markets.... ► Artikel lesen | |
| 12.06. | Nanoform Finland Oyj: Nanoform starts Pivotal Human Bioequivalence Studies of Nanoenzalutamide | 997 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | June 12, 2025 at 08:10:00 EEST
HELSINKI, FINLAND, June 12, 2025 - Nanoform Finland Plc, the medicine performance-enhancing company, today announced that it had... ► Artikel lesen | |
| 20.05. | Nanoform Finland Oyj: Nanoform Q1 2025 report: Deal mosaic emerge and commercial value clearly seen in our CESS technology | 1.291 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | May 20, 2025 at 08:10:00 EEST
Term sheets agreed for several key markets around nanoenzalutamide1). First term sheet also signed around nanoencorafenib2). Negotiations... ► Artikel lesen | |
| 15.04. | Nanoform Finland Oyj: Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc | 909 | GlobeNewswire (Europe) | Company release
Nanoform Finland Plc
April 15, 2025
14.10 Finnish time / 13.10 Swedish time
Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc
Nanoform Finland... ► Artikel lesen | |
| 27.02. | Nanoform Finland Oyj: Nanoform 2024 report: Deal discussions around product kernels intensify | 1.570 | GlobeNewswire (Europe) | Company Announcement
Nanoform Finland Plc
February 27, 2025
08:10 a.m. Finnish time / 07:10 a.m. Swedish time
Nanoform 2024 report: Deal discussions around product kernels intensify
After a strong... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 23,550 | -0,42 % | EQS-News: Formycon AG: Formycon und Zydus schließen exklusive Lizenz- und Liefervereinbarung für FYB206, ein Biosimilar für Keytruda (Pembrolizumab), in den USA und Kanada | EQS-News: Formycon AG
/ Schlagwort(e): Kooperation/Vereinbarung
Formycon und Zydus schließen exklusive Lizenz- und Liefervereinbarung für FYB206, ein Biosimilar für Keytruda (Pembrolizumab)... ► Artikel lesen | |
| ONTO INNOVATION | 132,00 | -1,49 % | Onto Innovation Inc. (ONTO): A Bull Case Theory | ||
| GAUZY | 1,140 | 0,00 % | Gauzy Ltd. - 6-K, Report of foreign issuer | ||
| KOPIN | 2,130 | -1,39 % | Kopin Corporation: Michael Murray, Kopin's CEO to Present at THEON International's Capital Markets Day (CMD) on November 6, 2025 | Kopin Corporation (NASDAQ: KOPN), a leading provider of application-specific optical systems and high-performance microdisplays for defense, training, enterprise, industrial, consumer and medical... ► Artikel lesen | |
| SOLESENCE | 1,970 | -4,60 % | Solésence, Inc.: Solésence Reports Third Quarter 2025 Financial Results | Advances Strategic Transformation with Key Changes in Executive Leadership, Product Development and Operations ROMEOVILLE, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN)... ► Artikel lesen | |
| VEECO INSTRUMENTS | 26,200 | 0,00 % | Veeco Instruments Inc.: Veeco Reports Third Quarter 2025 Financial Results | Third Quarter 2025 Highlights: Revenue of $165.9 million, compared with $184.8 million in the same period last yearGAAP net income of $10.6 million, or $0.17 per diluted share, compared with $22.0... ► Artikel lesen | |
| NANOLOGICA | 0,065 | 0,00 % | Nanologica AB: Interim Report Q3 2025 Nanologica AB (publ) | FINANCIAL SUMMARY Net sales for the third quarter amounted to SEK 2,843 thousand (611) and for the nine-month period to SEK 15,930 thousand (7,822)Operating loss for the quarter amounted to SEK -10... ► Artikel lesen | |
| NVE | 61,00 | +0,83 % | Dividendenbekanntmachungen (03.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADECOAGRO SA LU0584671464 0,1748 USD 0,1515 EUR AMERISERV FINANCIAL INC US03074A1025 0,03 USD 0,026 EUR AON PLC IE00BLP1HW54 0... ► Artikel lesen | |
| FENDX TECHNOLOGIES | 0,272 | -17,58 % | FendX Technologies Inc.: FendX Provides Corporate Update | Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company... ► Artikel lesen | |
| GOMSPACE | 1,424 | -3,78 % | GomSpace to provide RF subsystem for Apolink LEO relay demonstrator | ||
| DOTZ NANO | 0,029 | +3,64 % | DOTZ NANO LIMITED: Dotz Small Cap Investor Conference Highlights & Presentation | ||
| ACACIA RESEARCH | 3,180 | +1,27 % | Acacia Research Non-GAAP EPS of -$0.01 beats by $0.13, revenue of $59.4M beats by $21.4M | ||
| ADVANCE ZINCTEK | 0,620 | 0,00 % | ADVANCE ZINCTEK LIMITED: Response to Television Broadcast Early This Week | ||
| LAMPETIA | 0,068 | 0,00 % | EQS-News: Lampetia AG: Halbjahresfinanzbericht auf neuer Webseite | EQS-News: Lampetia AG
/ Schlagwort(e): Halbjahresbericht
LAMPETIA AG: Halbjahresfinanzbericht auf neuer Webseite
30.09.2025 / 19:51 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| NANOFOCUS | 1,810 | 0,00 % | HV-Termine: Hauptversammlungen bei bioXXmed, Borussia Dortmund, CureVac, elexxion, Nanofocus, NSI Asset, OTRS | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen |
NANOFORM FINLAND OYJ gehört der Branche Nanotechnologie an. Der aktuelle Kurs liegt bei 1,080 Euro und damit +9,31 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOFORM FINLAND OYJ finden Sie auf Wallstreet Online.